Asia/Oceania
Medigene Selects KRAS G12V Candidate Within WuXi TCR-Guided T-Cell Engager Collaboration
The firms partnered earlier this year to leverage each other's technologies and develop multiple T-cell receptor-guided T-cell engagers.
Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor
The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.
In Brief This Week: Mount Sinai, AAVantgarde Bio, Lantern Pharma, Exegenesis Bio, AlveoGene
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
Despite Overall Survival Miss, Singapore Researchers Champion Success of Global Cell Therapy Trial
Premium
The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell therapy to date.